Company Profile
HUTCHMED Stock Price, News & Catalysts
- Ticker:
- HCM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- China and listed in the U
Stock performance
12.56 USD (+2.95%)
Close
Last updated: August 17, 2026
1.98B USD
Market cap
Why the stock is moving
Following the latest company update, “HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EG…”, HCM closed up 2.95% at $12.56 on Aug 17, 2026. The move occurred in the trading session associated with this clinical readout update.
Company overview
China-Originated Oncology Company
HUTCHMED is an oncology-focused biopharmaceutical company with commercial products in China and partnered global products. Its strategy combines China commercialization, global partnerships, and internal R&D aimed at differentiated small molecules and newer antibody-targeted modalities.
Commercial Oncology Portfolio
The company's commercial base includes ELUNATE, SULANDA, FRUZAQLA, ORPATHYS, and other oncology products. First-half 2026 growth was led by a rebound in China product sales and geographic expansion of FRUZAQLA outside China, which had approvals or launches in 41 countries.
Late-Stage Regulatory Pipeline
HUTCHMED has multiple late-stage programs across oncology and immunology. Recent progress includes China approval of ELUNATE with sintilimab for second-line kidney cancer, China NDA acceptances for sovleplenib in wAIHA and ITP, ORPATHYS approval in third-line MET-amplified gastric cancer, and positive data for fanregratinib in FGFR2 fusion or rearrangement intrahepatic cholangiocarcinoma.
ATTC Innovation Strategy
The company is investing in antibody-targeted therapy conjugates, or ATTCs, that use antibody targeting to deliver potent small-molecule payloads to tumor cells. HMPL-A251, HMPL-A580, and HMPL-A830 represent a newer platform layer intended to create first-in-class or best-in-class candidates and support multinational partnering opportunities.
Future catalysts
- Topline results from SAFFRON and SANOVO Phase 3 savolitinib studies in the second half of 2026.
- NMPA review of sovleplenib in wAIHA and ITP.
- Global clinical trial initiation for HMPL-A830 in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of HUTCHMED (HCM)?
HUTCHMED (HCM) most recently closed at 12.56 USD, a +2.95% move versus the previous session.
What is the market cap of HUTCHMED (HCM)?
HUTCHMED currently has a market capitalization of 1.98B USD on BioPharmSignal.
What does HUTCHMED do?
China-Originated Oncology Company HUTCHMED is an oncology-focused biopharmaceutical company with commercial products in China and partnered global products. Its strategy combines China commercialization, global partnerships, and internal R&D aimed at differentiated small molecules and newer antibody-targeted modalities. Commercial Oncology Portfolio The...
On which exchange is HCM stock listed?
HUTCHMED (HCM) is associated with NASDAQ, China and listed in the U, Biopharma.
What is HMPL-A251?
HMPL-A251, HMPL-A580, and HMPL-A830 represent a newer platform layer intended to create first-in-class or best-in-class candidates and support multinational partnering opportunities.
Which conditions is HUTCHMED targeting with HMPL-A251?
HUTCHMED is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does HUTCHMED describe recent progress with HMPL-A251?
Topline results from SAFFRON and SANOVO Phase 3 savolitinib studies in the second half of 2026. NMPA review of sovleplenib in wAIHA and ITP. Global clinical trial initiation for HMPL-A830 in the second half of 2026.
What is HMPL-A580?
HMPL-A251, HMPL-A580, and HMPL-A830 represent a newer platform layer intended to create first-in-class or best-in-class candidates and support multinational partnering opportunities.